JP2020516655A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020516655A5 JP2020516655A5 JP2019555941A JP2019555941A JP2020516655A5 JP 2020516655 A5 JP2020516655 A5 JP 2020516655A5 JP 2019555941 A JP2019555941 A JP 2019555941A JP 2019555941 A JP2019555941 A JP 2019555941A JP 2020516655 A5 JP2020516655 A5 JP 2020516655A5
- Authority
- JP
- Japan
- Prior art keywords
- amhrii
- binding agent
- agent according
- seq
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 14
- 210000004027 cell Anatomy 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 3
- 230000000955 neuroendocrine Effects 0.000 claims description 3
- 208000009956 adenocarcinoma Diseases 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000000611 antibody drug conjugate Substances 0.000 claims 2
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 239000012099 Alexa Fluor family Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 241000283707 Capra Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17305446 | 2017-04-14 | ||
| EP17305446.1 | 2017-04-14 | ||
| PCT/EP2018/059553 WO2018189381A1 (en) | 2017-04-14 | 2018-04-13 | Amhrii-binding compounds for preventing or treating lung cancers |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2020516655A JP2020516655A (ja) | 2020-06-11 |
| JP2020516655A5 true JP2020516655A5 (cg-RX-API-DMAC7.html) | 2021-05-20 |
| JP7289420B2 JP7289420B2 (ja) | 2023-06-12 |
| JP7289420B6 JP7289420B6 (ja) | 2023-06-30 |
Family
ID=58672546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019555941A Active JP7289420B6 (ja) | 2017-04-14 | 2018-04-13 | 肺癌を予防又は処置する為のａｍｈｒｉｉ結合性化合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230227566A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3609919A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7289420B6 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20250017758A (cg-RX-API-DMAC7.html) |
| CN (1) | CN110944665B (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019021495A8 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3058541A1 (cg-RX-API-DMAC7.html) |
| MX (2) | MX2019012136A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018189381A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020516668A (ja) * | 2017-04-14 | 2020-06-11 | ガママブス ファルマ | 癌を予防又は処置する為のａｍｈｒｉｉ結合性化合物 |
| WO2020160217A1 (en) * | 2019-02-01 | 2020-08-06 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Microenvironment sensors to regulate engineered gene expression |
| CA3139956A1 (en) * | 2019-05-31 | 2020-12-03 | Laura DETTI | Anti-mullerian hormone receptor binding peptides |
| WO2021058744A1 (en) * | 2019-09-27 | 2021-04-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of müllerian inhibiting substance inhibitors for treating cancer |
| AU2021214795A1 (en) * | 2020-01-31 | 2022-08-18 | The Cleveland Clinic Foundation | Anti-Müllerian Hormone Receptor 2 antibodies and methods of use |
| AU2023222066A1 (en) * | 2022-02-16 | 2024-08-29 | The Cleveland Clinic Foundation | Amhr2-ed cancer vaccine formulations |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| DK1136556T3 (da) | 1991-11-25 | 2005-10-03 | Enzon Inc | Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| EP0770628B9 (en) | 1994-07-13 | 2007-02-28 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin-8 |
| EP1068241B1 (en) | 1998-04-02 | 2007-10-10 | Genentech, Inc. | Antibody variants and fragments thereof |
| US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| PL209786B1 (pl) | 1999-01-15 | 2011-10-31 | Genentech Inc | Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna |
| WO2005005615A2 (en) * | 2003-07-08 | 2005-01-20 | Fox Chase Cancer Center | Anti-mullerian inhibiting substance type ii receptor (misiir) immunoconjugates to detect and treat cancer |
| EP1918304A1 (en) | 2006-11-02 | 2008-05-07 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Monoclonal antibodies against the human anti-müllerian hormone type II receptor (AMHR-II) |
| US20100233689A1 (en) * | 2007-03-22 | 2010-09-16 | The General Hospital Corporation | Pyrazoloanthrone and derivatives thereof for the treatment of cancer expressing 'mullerian inhibiting substance' type ii receptor (misrii) and of excess androgen states |
| FR2959994B1 (fr) | 2010-05-12 | 2012-08-24 | Lfb Biotechnologies | Nouveaux anticorps humanises 12g4 mutes et leurs fragments diriges contre le recepteur humain de l'hormone anti-mullerienne de type ii |
| CA2837472A1 (en) * | 2011-05-27 | 2012-12-06 | Fox Chase Cancer Center | Rationally-designed anti-mullerian inhibiting substance type ii receptor antibodies |
| FR2984750B1 (fr) * | 2011-12-23 | 2014-01-10 | Lfb Biotechnologies | Nouvelles compositions pharmaceutiques comprenant un anticorps liant le recepteur humain de l'hormone anti-mullerienne de type ii |
| US10509035B2 (en) * | 2015-08-07 | 2019-12-17 | Gamamabs Pharma Sa | Antibodies, antibody drug conjugates and methods of use |
| WO2018148649A1 (en) * | 2017-02-10 | 2018-08-16 | The Institute For Cancer Research D/B/A | Chimera of bone morphogenic protein 2 and the müllerian-inhibiting substance type ii receptor binding region of mullerian-inhibiting substance |
| JP2020516668A (ja) | 2017-04-14 | 2020-06-11 | ガママブス ファルマ | 癌を予防又は処置する為のａｍｈｒｉｉ結合性化合物 |
-
2018
- 2018-04-13 KR KR1020257001888A patent/KR20250017758A/ko active Pending
- 2018-04-13 JP JP2019555941A patent/JP7289420B6/ja active Active
- 2018-04-13 CN CN201880040211.4A patent/CN110944665B/zh active Active
- 2018-04-13 CA CA3058541A patent/CA3058541A1/en active Pending
- 2018-04-13 WO PCT/EP2018/059553 patent/WO2018189381A1/en not_active Ceased
- 2018-04-13 EP EP18718420.5A patent/EP3609919A1/en active Pending
- 2018-04-13 BR BR112019021495A patent/BR112019021495A8/pt unknown
- 2018-04-13 US US16/605,053 patent/US20230227566A1/en not_active Abandoned
- 2018-04-13 MX MX2019012136A patent/MX2019012136A/es unknown
- 2018-04-13 KR KR1020197033360A patent/KR102759138B1/ko active Active
-
2019
- 2019-10-09 MX MX2024003228A patent/MX2024003228A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020516655A5 (cg-RX-API-DMAC7.html) | ||
| Wynn et al. | Anti-HER2 therapy in metastatic breast cancer: many choices and future directions | |
| AU2016244333B2 (en) | DLL3 modulators and methods of use | |
| JP2025072482A (ja) | キメラポックスウイルス組成物及びその使用 | |
| JP2016513094A5 (cg-RX-API-DMAC7.html) | ||
| ATE419516T1 (de) | Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc) | |
| EP4335931A3 (en) | Therapeutic and diagnostic methods for cancer | |
| RU2018107047A (ru) | Модифицированные моноциты/макрофаги, экспрессирующие химерные антигенные рецепторы, и их применения | |
| JP2019534891A (ja) | Ｈａａｒｔ安定化患者におけるｃｄ４に対する抗体によるｈｉｖ感染症の処置および持続的ウイルス学的寛解 | |
| JP2015506944A5 (cg-RX-API-DMAC7.html) | ||
| JP2016509582A5 (cg-RX-API-DMAC7.html) | ||
| González-Arenas et al. | Progesterone-induced blocking factor is hormonally regulated in human astrocytoma cells, and increases their growth through the IL-4R/JAK1/STAT6 pathway | |
| JP2019510739A5 (cg-RX-API-DMAC7.html) | ||
| JP2020516668A5 (cg-RX-API-DMAC7.html) | ||
| JP2018530331A5 (cg-RX-API-DMAC7.html) | ||
| Meghnani et al. | The receptor for advanced glycation end products influences the expression of its S100 protein ligands in melanoma tumors | |
| JP2015508063A5 (cg-RX-API-DMAC7.html) | ||
| Arnoldi et al. | Rotavirus increases levels of lipidated LC3 supporting accumulation of infectious progeny virus without inducing autophagosome formation | |
| Sanchorawala et al. | Safety and tolerability of daratumumab in patients with relapsed light chain (AL) amyloidosis: preliminary results of a phase II study | |
| Lee et al. | Oral reovirus reshapes the gut microbiome and enhances antitumor immunity in colon cancer | |
| WO2021150936A1 (en) | Oncolytic virus compositions including il-15 complex and methods for the treatment of cancer | |
| Hofbauer et al. | Arterial hypertension enhances neutrophil extracellular trap formation via an angiotensin-II-dependent pathway | |
| Borthwick et al. | Randomized phase I trial HIV-CORE 003: Depletion of serum amyloid P component and immunogenicity of DNA vaccination against HIV-1 | |
| Agaugue et al. | The high expression of NKG2D ligands on tumor and the lack of surface expression on healthy tissues provides a strong rationale to support NKG2D-based therapeutic approaches for cancer | |
| US20250186520A1 (en) | Oncolytic virus compositions and methods for the treatment of cancer |